Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Global Digital Dose Inhaler (Branded Medication, Generics Medication) Market 2016-2024: Focus on Metered Dose Inhalers & Dry Powder Inhalers - Research and Markets

DUBLIN, October 7, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Digital Dose Inhaler Market Analysis By Product (Metered Dose Inhaler, Dry Powder Inhaler), By Type (Branded Medication, Generics Medication) And Segment Forecasts to 2024" report to their offering.

The global digital dose inhaler market is anticipated to reach a value of USD 3.56 billion by 2024

The key factors contributing to the lucrative growth of this market include the continually increasing elderly population and the surging prevalence of chronic respiratory diseases.

As a result of impactful economic developments in the fast emerging countries, such as China, India, Brazil, Philippines, and others, there has been growth in the per capita income, which is thus expected to influence the demand for the technologically advanced respiratory devices. Moreover, these technology-enabled respiratory devices are greatly sought after among the pediatric and the geriatric population so as to improve the patient medication compliance, dose tracking, and to enhance patient-healthcare practitioner connectivity that would enable real-time tracking of healthcare data; these serve as high impact rendering factors, significantly driving the market growth in the next nine years.

In order to cater to the unmet needs of the target population, the vendors are expanding their production units and in addition, targeting the niche areas where the prevalence of chronic lung diseases and asthma are on the rise, such as Asia Pacific and MEA regions, to ensure long-term growth and profitability. Therefore, the aforementioned, business expansion trends are expected to boost the usage rates of the digital dose inhalers over the forecast period.

Additionally, favorable government initiatives, such as the introduction of Fixed Dose Combination (FDC), advanced by the U.S. FDA, fast increasing adoption of generic drugs, and the growing demand for digital health platforms are the identified crucial determinants influencing the rapid uptake of these digital inhalers, which is expected to continue in the coming years.

Rapidly increasing geriatric population worldwide in conjunction with the growing prevalence of various chronic respiratory conditions, such as chronic sleep apnea, asthma, COPD, among others negatively impact healthcare system. This would further escalate the demand for innovative respiratory devices thereby encouraging the digital dose inhalers market growth during the forecast period.

Further key findings from the study suggest:

  • In 2015, the metered dose inhalers (MDIs) segment accounted for the maximum revenue of USD 563.9 million, mainly on account of the increased preference for MDIs.
  • However, the dry powder inhalers (DPIs) segment is expected to emerge as the fastest growing category with a CAGR of 16.9% over the forecast period owing to the growing awareness regarding the adverse effects of chlorofluorocarbons employed as a propellant in the MDIs.
  • In 2015, the branded medication respiratory devices category accounted for the largest market share of USD 747.6 million attributable to the steadily growing need for advanced respiratory drugs and the awareness related to the benefits of combination medication gaining prominence.
  • North America held the maximum share of over 38.64% in 2015. This large share is attributed to the presence of several medical device players in this region, such as Johnson & Johnson, Cohera Medical, Inc., Teleflex Medical, Inc., Covidien Plc, and others.
  • The Asia Pacific (APAC) region is anticipated to grow at a lucrative pace with a CAGR of 17.2% over the forecast period.

Some leading players of the market include

  • Glenmark Pharmaceuticals Ltd.
  • Novartis International AG
  • Propeller Health
  • AstraZeneca Plc
  • Philips Respironics
  • Teva Pharmaceutical Industries Ltd.
  • Opko Health, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/sw6x38/digital_dose

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.